IBC’s Pharma Legal Affairs Asia 2013

EXHIBITOR'S PROFILE:

How You Can Benefit in  Pharma Legal Affairs Asia 2013?

• Update and review the latest changes in laws governing Asia’s key emerging  markets (India, China & SEA)
• Enhance your partnering and licensing strategies and extend your drafting and negotiation skills
• Protect market share through deep insights into regional regimes’ IP legal framework, particularly in China
• Mitigate the risk of violating FCPA, anti-corruption and other anti-bribery laws via violation case reviews and program set up

Develop the most effective cost effective patent litigation strategy 

The pharma industry is witnessing drastic changes across sectors and regions. Regardless of your business, there are numerous hurdles to face;

• The fallout from patent cliff expiries continues and with it, in 2013, Big Pharma innovators’ struggle to preserve market share and profitability. This is a critical time to review available options to protect your IP assets and stay competitive
• For the Generics and Biosimilars industry, increasing legal challenges, ongoing price erosion and stringent manufacturing compliance requirements threaten sustainability. Updates on how to address and defend changes are essential
• In recent decades, global drug makers have paid tens of millions of dollars to settle US allegations that they bribed their way across emerging markets. US enforcers co-operate with their foreign counterparts in the implementation of the FCPA, leading to multi-jurisdictional litigations/investigations.
• During this critical period, numerous partnerships formed to face these challenges. How will these fare and how can they reinforce their licensing/ distribution/ manufacturing contracts to maximize the benefits while mitigating risks?